Conditioning vaccination site with irradiated MIP-3α-transfected tumor cells enhances efficacy of dendritic cell-based cancer vaccine

Journal of Immunotherapy

Volumn 32, Issue 4, 2009, Pages 363-369

  Shih, Neng Yao ^a   Yang, Hui Yu ^a   Cheng, Hui Ting ^a   Hung, Yi Mei ^a   Yao, Yi Chuan ^a   Zhu, Yun Han ^a   Wu, Yu Chen ^a   Liu, Ko Jiunn ^a,b  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cancer vaccine; Dendritic cells; Macrophage inflammation protein 3a

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER IMMUNIZATION; CANCER INHIBITION; CELL BASED GENE THERAPY; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; GENETIC TRANSFECTION; LUNG METASTASIS; MELANOMA; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; ANIMAL; C57BL MOUSE; CELL MOTION; DENDRITIC CELL; EXPERIMENTAL MELANOMA; IMMUNOLOGY; LUNG TUMOR; METASTASIS; TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CCL20; DENDRITIC CELLS; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; TRANSFECTION;

EID: 67449101536     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31819d29d8     Document Type: Article

References (27)

1. Stift A, Friedl J, Dubsky P, et al. Dendritic cell-based vaccination in solid cancer. J Clin Oncol. 2003;21:135-142.
2. Palucka AK, Ueno H, Fay JW, et al. Taming cancer by inducing immunity via dendritic cells. Immunol Rev. 2007;220: 129-150.
3. DeMatos P, Abdel-Wahab Z, Vervaert C, et al. Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6mice. Cell Immunol. 1998; 185:65-74.
4. DeMatos P, Abdel-Wahab Z, Vervaert C, et al. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice. J Surg Oncol. 1998;68:79-91.
5. Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA. 1998; 95:9482-9487.
6. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2:52-58.
7. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells [see comments]. Nat Med. 1998;4:328-332.
8. Tjoa BA, Simmons SJ, Bowes VA, et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate. 1998;36:39-44.
9. *2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin Cancer Res. 2004;10:2645-2651.
10. Chang GC, Lan HC, Juang SH, et al. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma. Cancer. 2005;103:763-771.
11. Parmiani G, Rodolfo M, Melani C. Immunological gene therapy with ex vivo gene-modified tumor cells: a critique and a reappraisal. Hum Gene Ther. 2000;11:1269-1275.
12. Jaffee EM, Abrams R, Cameron J, et al. A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. Hum Gene Ther. 1998;9:1951-1971.
13. Greten TF, Jaffee EM. Cancer vaccines. J Clin Oncol. 1999; 17:1047-1060.
14. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst. 1997; 89:21-39.
15. Martín-Fontecha A, Sebastiani S, Hopken UE, et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med. 2003;198:615-621.
16. + T cells. Cancer Gene Ther. 2004; 11:135-147.
17. Dieu-Nosjean MC, Vicari A, Lebecque S, et al. Regulation of dendritic cell trafficking: a process that involves the participation of selective chemokines. J Leukoc Biol. 1999;66: 252-262.
18. Charbonnier AS, Kohrgruber N, Kriehuber E, et al. Macrophage inflammatory protein 3alpha is involved in the constitutive trafficking of epidermal Langerhans cells. J Exp Med. 1999;190:1755-1768.
19. Dieu MC, Vanbervliet B, Vicari A, et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med. 1998; 188: 373-386.
20. Dieu-Nosjean MC, Massacrier C, Homey B, et al. Macrophage inflammatory protein 3alpha is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors. J Exp Med. 2000; 192:705-718.
21. Akahoshi T, Sasahara T, Namai R, et al. Production of macrophage inflammatory protein 3alpha (MIP-3alpha) (CCL20) and MIP-3beta (CCL19) by human peripheral blood neutrophils in response to microbial pathogens. Infect Immun. 2003;71:524-526.
22. Yang D, Chen Q, Hoover DM, et al. Many chemokines including CCL20/MIP-3alpha display antimicrobial activity. J Leukoc Biol. 2003;74:448-455.
23. Mackey MF, Gunn JR, Maliszewsky C, et al. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J Immunol. 1998;161:2094-2098.
24. Fushimi T, Kojima A, Moore MA, et al. Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J Clin Invest. 2000;105:1383-1393.
25. Zhu B, Zou L, Cheng X, et al. Administration of MIP-3alpha gene to the tumor following radiation therapy boosts antitumor immunity in a murine model of lung carcinoma. Immunol Lett. 2006;103:101-107.
26. + T cell crosspriming in vivo. Immunity. 2006;24:191-201.
27. + CTL to cause tumor eradication. J Immunol. 2004;173:6753-6759.